The impact of proton LET/RBE modeling and robustness analysis on base-of-skull and pediatric craniopharyngioma proton plans relative to VMAT

References

• Diller L, Chow EJ, Gurney JG, et al. Chronic disease in the childhood cancer survivor study cohort: a review of published findings. JCO. 2009;27:2339–2355.
   PubMed Web of Science ®Google Scholar
• Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res. 2010;174:840–850.
   PubMed Web of Science ®Google Scholar
• Yock TI, Bhat S, Szymonifka J, et al. Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiother Oncol. 2014;113:89–94.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Brown PD, Foote RL. Protons vs photons for brain and skull base tumors. Semin Radiat Oncol. 2018;28:97–107.
   PubMed Web of Science ®Google Scholar
• Beltran C, Roca M, Merchant TE. On the benefits and risks of proton therapy in pediatric craniopharyngioma. Int J Radiat Oncol Biol Phys. 2012;82:e281–e287.
   PubMedGoogle Scholar
• Boehling NS, Grosshans DR, Bluett JB, et al. Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas. Int J Radiat Oncol Biol Phys. 2012;82:643–652.
   PubMed Web of Science ®Google Scholar
• Torres MA, Chang EL, Mahajan A, et al. Optimal treatment planning for skull base chordoma: photons, protons, or a combination of both?. Int J Radiat Oncol Biol Phys. 2009;74:1033–1039.
   PubMed Web of Science ®Google Scholar
• Feuvret L, Noel G, Weber DC, et al. A treatment planning comparison of combined photon–proton beams versus proton beams–only for the treatment of skull base tumors. Int J Radiat Oncol Biol Phys. 2007;69:944–954.
   PubMed Web of Science ®Google Scholar
• Fossati P, Vavassori A, Deantonio L, et al. Review of photon and proton radiotherapy for skull base tumours. Rep Pract Oncol Radiother. 2016;21:336–355.
   PubMedGoogle Scholar
• Hug EB, Loredo LN, Slater JD, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg. 1999;91:432–439.
   PubMed Web of Science ®Google Scholar
• Yock AD, Mohan R, Flampouri S, et al. Robustness analysis for external beam radiation therapy treatment plans: Describing uncertainty scenarios and reporting their dosimetric consequences. Pract Radiat Oncol. 2018;9:200–207.
   PubMed Web of Science ®Google Scholar
• Unkelbach J, Paganetti H. Robust proton treatment planning: physical and biological optimization. Semin Radiat Oncol. 2018;28:88–96.
   PubMed Web of Science ®Google Scholar
• McGowan SE, Albertini F, Thomas SJ, et al. Defining robustness protocols: a method to include and evaluate robustness in clinical plans. Phys Med Biol. 2015;60:2671–2684.
   PubMed Web of Science ®Google Scholar
• Liu W, Mohan R, Park P, et al. Dosimetric benefits of robust treatment planning for intensity modulated proton therapy for base-of-skull cancers. Pract Radiat Oncol. 2014;4:384–391.
   PubMedGoogle Scholar
• ICRU. Prescribing, recording, and reporting proton-beam therapy. J Int Comm Rad Units Measure. 2008;7:21–28.
   Google Scholar
• Guan F, Bronk L, Titt U, et al. Spatial mapping of the biologic effectiveness of scanned particle beams: towards biologically optimized particle therapy. Sci Rep. 2015;5:9850.
   PubMed Web of Science ®Google Scholar
• Perris A, Pialoglou P, Katsanos AA, et al. Biological effectiveness of low energy protons. I. Survival of Chinese hamster cells. Int. J. Radiat. Biol. 1986;50:1093–1101.
   Web of Science ®Google Scholar
• Belli M, Cherubini R, Finotto S, et al. RBE-LET relationship for the survival of V79 cells irradiated with low energy protons. Int J Radiat Biol. 1989;55:93–104.
   PubMed Web of Science ®Google Scholar
• Belli M, Cera F, Cherubini R, et al. RBE-LET relationship for survival and mutation induction of V79 cells irradiated with low-energy protons: re-evaluation of the LET values at the LNL facility. Int J Radiat Biol. 1992;61:145–146.
   Web of Science ®Google Scholar
• Wouters BG, Sy AM, Skarsgard LD. Low-dose hypersensitivity and increased radioresistance in a panel of human tumor cell lines with different radiosensitivity. Radiat Res. 1996;146:399–413.
   PubMed Web of Science ®Google Scholar
• Folkard M, Prise KM, Vojnovic B, et al. Inactivation of V79 cells by low-energy protons, deuterons and helium-3 ions. Int J Radiat Biol. 1996;69:729–738.
   PubMed Web of Science ®Google Scholar
• Coutrakon G, Cortese J, Ghebremedhin A, et al. Microdosimetry spectra of the Loma Linda proton beam and relative biological effectiveness comparisons. Med Phys. 1997;24:1499–1506.
   PubMed Web of Science ®Google Scholar
• Schettino G, Folkard M, Prise KM, et al. Low-dose hypersensitivity in Chinese hamster V79 cells targeted with counted protons using a charged-particle microbeam. Radiat Res. 2001;156:526–534.
   PubMed Web of Science ®Google Scholar
• Paganetti H. Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer. Phys Med Biol. 2014;59:R419–R472.
   PubMed Web of Science ®Google Scholar
• Underwood T, Giantsoudi D, Moteabbed M, et al. Can we advance proton therapy for prostate? considering alternative beam angles and relative biological effectiveness variations when comparing against intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2016;95:454–464.
   PubMed Web of Science ®Google Scholar
• Underwood TSA, Voog JC, Moteabbed M, et al. Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams. Acta Oncol. 2017;56:575–581.
   PubMed Web of Science ®Google Scholar
• Rørvik E, Fjaera LF, Dahle TJ, et al. Exploration and application of phenomenological RBE models for proton therapy. Phys Med Biol. 2018;63:185013.
   PubMed Web of Science ®Google Scholar
• Ödén J, Eriksson K, Toma-Dasu I. Inclusion of a variable RBE into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy. Med Phys. 2017;44:810–822.
   PubMed Web of Science ®Google Scholar
• Pedersen J, Petersen JBB, Stokkevåg CH, et al. Biological dose and complication probabilities for the rectum and bladder based on linear energy transfer distributions in spot scanning proton therapy of prostate cancer. Acta Oncol. 2017;56:1413–1419.
   PubMed Web of Science ®Google Scholar
• Ödén J, Eriksson K, Toma-Dasu I. Incorporation of relative biological effectiveness uncertainties into proton plan robustness evaluation. Acta Oncol. 2017;56:769–778.
   PubMed Web of Science ®Google Scholar
• Yepes P, Adair A, Frank JS, et al. Fixed- versus variable-RBE computations for intensity modulated proton therapy. Adv Radiat Oncol. 2019;4:156–167.
   PubMedGoogle Scholar
• Carabe A, España S, Grassberger C, et al. Clinical consequences of relative biological effectiveness variations in proton radiotherapy of the prostate, brain and liver. Phys Med Biol. 2013;58:2103–2117.
   PubMed Web of Science ®Google Scholar
• Tilly N, Johansson J, Isacsson U, et al. The influence of RBE variations in a clinical proton treatment plan for a hypopharynx cancer. Phys Med Biol. 2005;50:2765–2777.
   PubMed Web of Science ®Google Scholar
• Giovannini G, Böhlen T, Cabal G, et al. Variable RBE in proton therapy: comparison of different model predictions and their influence on clinical-like scenarios. Radiat Oncol. 2016;11:68.
   PubMed Web of Science ®Google Scholar
• Wedenberg M, Toma DI. Disregarding RBE variation in treatment plan comparison may lead to bias in favor of proton plans. Med Phys. 2014;41:091706.
   PubMed Web of Science ®Google Scholar
• Giantsoudi D, Adams J, MacDonald SM, et al. Proton treatment techniques for posterior fossa tumors: consequences for linear energy transfer and dose-volume parameters for the brainstem and organs at risk. Int J Radiat Oncol Biol Phys. 2017;97:401–410.
   PubMed Web of Science ®Google Scholar
• Lambrecht M, Eekers DBP, Alapetite C, et al. Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. Radiat Oncol. 2018;128:26–36.
   Web of Science ®Google Scholar
• Pflugfelder D, Wilkens JJ, Oelfke U. Worst case optimization: a method to account for uncertainties in the optimization of intensity modulated proton therapy. Phys Med Biol. 2008;53:1689–1700.
   PubMed Web of Science ®Google Scholar
• Fredriksson A, Forsgren A, Hårdemark B. Minimax optimization for handling range and setup uncertainties in proton therapy. Med Phys. 2011;38:1672–1684.
   PubMed Web of Science ®Google Scholar
• Paganetti H. Range uncertainties in proton therapy and the role of Monte Carlo simulations. Phys Med Biol. 2012;57:R99–R117.
   PubMed Web of Science ®Google Scholar
• Jäkel O, Debus J. Selection of beam angles for radiotherapy of skull base tumours using charged particles. Phys Med Biol. 2000;45:1229–1241.
   PubMed Web of Science ®Google Scholar
• McNamara AL, Schuemann J, Paganetti H. A phenomenological relative biological effectiveness (RBE) model for proton therapy based on all published in vitro cell survival data. Phys Med Biol. 2015;60:8399–8416.
   PubMed Web of Science ®Google Scholar
• Deasy JO, Blanco AI, Clark VH. CERR: a computational environment for radiotherapy research. Med Phys. 2003;30:979–985.
   PubMed Web of Science ®Google Scholar
• van Leeuwen CM, Oei AL, Crezee J, et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol. 2018;13:96.
   PubMed Web of Science ®Google Scholar
• Fraser C, Henderson FC, McCool K, Seigle J, et al. Treatment of chordomas with cyberknife: Georgetown University experience and treatment recommendations. Neurosurgery. 2009;64:A44–A53.
   PubMed Web of Science ®Google Scholar
• Sanchez-Parcerisa D, Cortés-Giraldo MA, Dolney D, et al. Analytical calculation of proton linear energy transfer in voxelized geometries including secondary protons. Phys Med Biol. 2016;61:1705–1721.
   PubMed Web of Science ®Google Scholar
• Jones B, Dale RG, Deehan C, et al. The role of Biologically Effective Dose (BED) in clinical oncology. Clin Oncol. 2001;13:71–81.
   PubMed Web of Science ®Google Scholar
• Underwood TSA, McMahon SJ. Proton relative biological effectiveness (RBE): a multiscale problem. BJR. 2018;91:20180004.
   Google Scholar
• W L. Robustness quantification and worst-case robust optimization in intensity-modulated proton therapy. In: Rath A., Sahoo N, editors. Particle radiotherapy. New Delhi, India: Springer; 2016.
   Google Scholar
• Wagenaar D, Kierkels RGJ, Langendijk JA, et al. Composite minimax robust optimization of VMAT improves target coverage and reduces non-target dose in head and neck cancer patients. Radiother Oncol. 2019;136:71–77.
   PubMed Web of Science ®Google Scholar
• Liu W, Patel SH, Shen JJ, et al. Robustness quantification methods comparison in volumetric modulated arc therapy to treat head and neck cancer. Pract Radiat Oncol. 2016;6:e269–e275.
   PubMed Web of Science ®Google Scholar
• Unkelbach J, Botas P, Giantsoudi D, et al. Reoptimization of intensity modulated proton therapy plans based on linear energy transfer. Int J Radiat Oncol Biol Phys. 2016;96:1097–1106.
   PubMed Web of Science ®Google Scholar
• An Y, Shan J, Patel SH, et al. Robust intensity-modulated proton therapy to reduce high linear energy transfer in organs at risk. Med Phys. 2017;44:6138–6147.
   PubMed Web of Science ®Google Scholar
• Wan Chan Tseung HS, Ma J, Kreofsky CR, et al. Clinically applicable Monte Carlo-based biological dose optimization for the treatment of head and neck cancers with spot-scanning proton therapy. Int J Radiat Oncol Biol Phys. 2016;95:1535–1543.
   PubMed Web of Science ®Google Scholar
• Lühr A, von Neubeck C, Krause M, et al. Relative biological effectiveness in proton beam therapy – current knowledge and future challenges. Clin Translat Radiat Oncol. 2018;9:35–41.
   PubMed Web of Science ®Google Scholar
• Underwood T, Paganetti H. Variable proton relative biological effectiveness: how do we move forward? Int J Radiat Oncol Biol Phys. 2016;95:56–58.
   PubMed Web of Science ®Google Scholar